MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/rlu.0000000000006582

Медицинская библиотека · Clinical nuclear medicine · 2026

Clinical Value of 68 Ga-DOTA-Bombesin PET/CT Compared With 18 F-FDG PET/CT in the Staging of Breast Cancer.

Baloglu Mehmet Can, Şahin Rahime, Tosunoglu Zehranur, Ozturk Ahmet Ertugrul, Şahin Ömer Faruk, Beyhan Ediz, Erol Fenercioglu Özge, Alcin Göksel, Ergul Nurhan, Cermik Tevfik Fikret, Usul Afsar Çiğdem, Arslan Esra

СтатьяСравнительное исследованиеПеревод в очереди

Аннотация

AIM: To prospectively evaluate the diagnostic performance of 68 Ga-DOTA-Bombesin PET/CT compared with 18 F-FDG PET/CT in breast cancer (BC), emphasizing its utility across molecular subtypes and nodal staging.

PATIENTS AND

METHODS

Twenty-four patients with biopsy-proven BC who underwent both 68 Ga-DOTA-Bombesin and 18 F-FDG PET/CT were included. Imaging findings were analyzed on a per-lesion and per-patient basis for primary tumor detection, axillary lymph-node involvement, and distant metastases. Quantitative parameters (SUVmax, MTV, and tumor-to-background ratios) were compared across histopathologic and receptor subgroups, with histopathology as the reference standard.

RESULTS

68 Ga-DOTA-Bombesin visualized 92.3% of primary tumors, achieving comparable sensitivity to 18 F-FDG (84.6%) but higher specificity in nodal staging (100% vs. 53.8%). Bombesin uptake correlated strongly with estrogen receptor positivity and a lower Ki-67 index ( P <0.05). In a limited number of patients with distant metastases (n=4), FDG appeared to detect hepatic and pulmonary lesions, whereas Bombesin identified additional osseous and peritoneal lesions. Physiological uptake was lower in the liver and bone marrow but higher in the blood pool for Bombesin. Emerging antagonist data indicate further improvements in tumor-to-background ratios and potential theranostic applications.

CONCLUSIONS

68 Ga-DOTA-Bombesin PET/CT provides a receptor-specific imaging approach in BC, showing complementary strengths to 18 F-FDG, particularly in hormone-receptor-positive and low-proliferation tumors. Its superior nodal specificity and theranostic potential support further evaluation of GRPR-targeted imaging and therapy in personalized BC management.

Для цитирования: Baloglu Mehmet Can, Şahin Rahime, Tosunoglu Zehranur, Ozturk Ahmet Ertugrul, Şahin Ömer Faruk, Beyhan Ediz, Erol Fenercioglu Özge, Alcin Göksel, Ergul Nurhan, Cermik Tevfik Fikret, Usul Afsar Çiğdem, Arslan Esra. Clinical Value of 68 Ga-DOTA-Bombesin PET/CT Compared With 18 F-FDG PET/CT in the Staging of Breast Cancer.. Clinical nuclear medicine. 2026. DOI: 10.1097/rlu.0000000000006582.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.